Cartesian Therapeutics, Inc.
RNAC•NASDAQ•Healthcare•Biotechnology

About Cartesian Therapeutics

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous anti-BCMA mRNA CAR-T to treat autoimmune diseases, such as relapsed/refractory multiple myeloma. The company is headquartered in Frederick, Maryland.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOCarsten Brunn
Founded2007
IPO DateJune 22, 2016
Employees66
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Corporate Identifiers

CIK0001453687
CUSIP816212302
ISINUS8162123025
SIC2834

Leadership Team & Key Executives

Dr. Carsten Brunn Ph.D.
President, Chief Executive Officer and Chairman of the Board
Blaine T. Davis
Chief Financial Officer
Dr. Metin Kurtoglu M.D., Ph.D.
Consultant
Dr. Emily English Ph.D.
Chief Operating Officer
June Seymour
Chief Accounting Officer
Matthew Bartholomae J.D.
General Counsel and Secretary
Dr. Milos Miljkovic M.D., Ph.D.
Chief Medical Officer